Rigel Pharmaceuticals Inc. Watch

from 10-Q 12 pages Certain Confidential Information Contained in This Document, Marked by [**], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. ​ 4th Amendment to the Collaboration and License Agreement

from 10-Q 18 pages Certain Confidential Information Contained in This Document, Marked by [**], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. ​ ​ Supply Agreement

from 10-Q 52 pages Certain Confidential Information Contained in This Document, Marked by [**], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential

from 10-Q 14 pages Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended by the Compensation Committee: August 19, 2020 Amended by the Compensation Committee: September 30, 2021 Amended by the Compensation Committee: January 4, 2022 Amended by the Compensation Committee: April 4, 2022 Amended by the Compensation Committee: December 8, 2022 Amended by the Compensation Committee: April 4, 2023 Amended by the Compensation Committee: June 29, 2023 Amended by the Compensation Committee: October 3, 2023 Amended by the Compensation Committee: December 26, 2023 Amended by the Compensation Committee: March 26, 2024 Amended by the Compensation Committee: April 4, 2024 Amended by the Compensation Committee: July 8, 2024 ​ ​

from 10-Q 20 pages Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23,2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 Amended January 28, 2021 Amended March 9, 2021 Approved by the Stockholders: May 18, 2021 Approved by the Stockholders: May 19, 2022 Approved by the Stockholders: May 25, 2023 Approved by the Stockholders: May 24, 2024 ​ ​ ​

from 10-Q 13 pages Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended by the Compensation Committee: August 19, 2020 Amended by the Compensation Committee: September 30, 2021 Amended by the Compensation Committee: January 4, 2022 Amended by the Compensation Committee: April 4, 2022 Amended by the Compensation Committee: December 8, 2022 Amended by the Compensation Committee: April 4, 2023 Amended by the Compensation Committee: June 29, 2023 Amended by the Compensation Committee: October 3, 2023 Amended by the Compensation Committee: December 26, 2023 Amended by the Compensation Committee: March 26, 2024 Amended by the Compensation Committee: April 4, 2024 ​

from 10-Q 17 pages ​ Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential

from 10-Q 2 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. ​ ​ Amendment No. 2 to the License and Collaboration Agreement ​

from 10-Q 68 pages ​ Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Asset Purchase Agreement Between Blueprint Medicines Corporation and Rigel Pharmaceuticals, Inc. Dated as of February 22, 2024

from 10-K 13 pages Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended by the Compensation Committee: August 19, 2020 Amended by the Compensation Committee: September 30, 2021 Amended by the Compensation Committee: January 4, 2022 Amended by the Compensation Committee: April 4, 2022 Amended by the Compensation Committee: December 8, 2022 Amended by the Compensation Committee: April 4, 2023 Amended by the Compensation Committee: June 29, 2023 Amended by the Compensation Committee: October 3, 2023 Amended by the Compensation Committee: December 26, 2023 ​

from 10-Q 3 pages ​ Amendment No. 1 to the License and Collaboration Agreement ​

from 10-Q 24 pages ​ Rigel Pharmaceuticals, Inc. Amended and Restated Executive Severance Plan

from 10-Q 11 pages Amendment 1 to License and Transition Services Agreement

from 10-Q 13 pages Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended by the Compensation Committee: August 19, 2020 Amended by the Compensation Committee: September 30, 2021 Amended by the Compensation Committee: January 4, 2022 Amended by the Compensation Committee: April 4, 2022 Amended by the Compensation Committee: December 8, 2022 Amended by the Compensation Committee: April 4, 2023 Amended by the Compensation Committee: July 6, 2023 ​

from 10-Q 20 pages Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23,2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 Amended January 28, 2021 Amended March 9, 2021 Approved by the Stockholders: May 18, 2021 Approved by the Stockholders: May 19, 2022 Approved by the Stockholders: May 25, 2023 ​ ​ ​

from 10-K 3 pages ​ November 17, 2022 ​ Raymond Furey [***] ​ Re: Employment Terms ​ Dear Raymond: ​ Rigel Pharmaceuticals, Inc. (The Company) Is Pleased to Offer You the Position of Executive Vice President and General Counsel on the Terms Set Forth in This Letter. ​

from 10-K 13 pages ​ Sublease Agreement

from 10-K 13 pages Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended by the Compensation Committee: August 19, 2020 Amended by the Compensation Committee: September 30, 2021 Amended by the Compensation Committee: January 4, 2022 Amended by the Compensation Committee: April 4, 2022 Amended by the Compensation Committee: December 8, 2022 ​

from 10-Q 95 pages Agreement

from 10-Q 79 pages ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ License and Transition Services Agreement by and Between Rigel Pharmaceuticals, Inc., and Forma Therapeutics, Inc. July 27, 2022